CL2023001195A1 - Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades. - Google Patents
Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades.Info
- Publication number
- CL2023001195A1 CL2023001195A1 CL2023001195A CL2023001195A CL2023001195A1 CL 2023001195 A1 CL2023001195 A1 CL 2023001195A1 CL 2023001195 A CL2023001195 A CL 2023001195A CL 2023001195 A CL2023001195 A CL 2023001195A CL 2023001195 A1 CL2023001195 A1 CL 2023001195A1
- Authority
- CL
- Chile
- Prior art keywords
- diseases
- treatment
- bicyclic compounds
- compounds
- compositions
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108660P | 2020-11-02 | 2020-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001195A1 true CL2023001195A1 (es) | 2023-10-20 |
Family
ID=81384389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001195A CL2023001195A1 (es) | 2020-11-02 | 2023-04-26 | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades. |
| CL2024000340A CL2024000340A1 (es) | 2020-11-02 | 2024-02-02 | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000340A CL2024000340A1 (es) | 2020-11-02 | 2024-02-02 | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240025903A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4236944A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7884275B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230104191A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116568301A (cg-RX-API-DMAC7.html) |
| AR (1) | AR124637A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021371026A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3196582A1 (cg-RX-API-DMAC7.html) |
| CL (2) | CL2023001195A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302465A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004942A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI918751B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022094400A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313039A (en) * | 2021-12-17 | 2024-07-01 | Athira Pharma Inc | Uses of bicyclic compounds for the treatment of diseases |
| KR20250005323A (ko) * | 2022-05-04 | 2025-01-09 | 아티라 파마, 인코포레이티드 | 신경병증을 치료하는 방법 |
| US20250275976A1 (en) * | 2022-05-04 | 2025-09-04 | Athira Pharma, Inc. | Methods of Treating Neuroinflammatory Conditions |
| JP2025538382A (ja) | 2022-11-18 | 2025-11-28 | アティラ・ファーマ・インコーポレイテッド | 炎症病態を治療する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| WO2004035587A1 (en) | 2002-10-17 | 2004-04-29 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
| US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| WO2006036981A2 (en) * | 2004-09-28 | 2006-04-06 | Angion Biomedica Corp. | Small molecule modulators of cytokine activity |
| US7879898B1 (en) * | 2006-02-14 | 2011-02-01 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease |
| EP1947085A1 (en) * | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| US8691819B2 (en) * | 2008-10-14 | 2014-04-08 | Prism Biolab Corporation | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions |
| US20160074400A1 (en) * | 2012-08-06 | 2016-03-17 | University Of Southern California | Wnt modulators for the protection, mitigation and treatment of radiation injury |
| EP3366687B1 (en) * | 2015-09-18 | 2020-04-29 | National University Corporation Tottori University | Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis |
-
2021
- 2021-11-01 AU AU2021371026A patent/AU2021371026A1/en active Pending
- 2021-11-01 EP EP21887720.7A patent/EP4236944A4/en active Pending
- 2021-11-01 US US18/032,918 patent/US20240025903A1/en active Pending
- 2021-11-01 MX MX2023004942A patent/MX2023004942A/es unknown
- 2021-11-01 TW TW110140600A patent/TWI918751B/zh active
- 2021-11-01 JP JP2023551946A patent/JP7884275B2/ja active Active
- 2021-11-01 IL IL302465A patent/IL302465A/en unknown
- 2021-11-01 AR ARP210103033A patent/AR124637A1/es unknown
- 2021-11-01 KR KR1020237018061A patent/KR20230104191A/ko active Pending
- 2021-11-01 CN CN202180079749.8A patent/CN116568301A/zh active Pending
- 2021-11-01 CA CA3196582A patent/CA3196582A1/en active Pending
- 2021-11-01 WO PCT/US2021/057563 patent/WO2022094400A1/en not_active Ceased
- 2021-11-01 CN CN202411623883.1A patent/CN119684295A/zh active Pending
-
2023
- 2023-04-26 CL CL2023001195A patent/CL2023001195A1/es unknown
-
2024
- 2024-02-02 CL CL2024000340A patent/CL2024000340A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4236944A1 (en) | 2023-09-06 |
| TWI918751B (zh) | 2026-03-21 |
| CL2024000340A1 (es) | 2024-08-16 |
| CN116568301A (zh) | 2023-08-08 |
| US20240025903A1 (en) | 2024-01-25 |
| CN119684295A (zh) | 2025-03-25 |
| CA3196582A1 (en) | 2022-05-05 |
| AU2021371026A1 (en) | 2023-06-15 |
| JP2023550543A (ja) | 2023-12-01 |
| AU2021371026A9 (en) | 2024-04-18 |
| JP7884275B2 (ja) | 2026-07-03 |
| KR20230104191A (ko) | 2023-07-07 |
| AR124637A1 (es) | 2023-04-19 |
| IL302465A (en) | 2023-06-01 |
| TW202233622A (zh) | 2022-09-01 |
| MX2023004942A (es) | 2023-07-06 |
| EP4236944A4 (en) | 2024-09-04 |
| WO2022094400A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000340A1 (es) | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades | |
| CO2022002759A2 (es) | Antagonistas de hpk1 y sus usos | |
| CO2021007993A2 (es) | Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina | |
| MX2021007468A (es) | Compuestos que participan en la union cooperativa y usos de los mismos. | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CL2020002573A1 (es) | Inhibidores atf6 y sus usos. | |
| DOP2020000040A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| PA8570701A1 (es) | Compuestos que modulan la actividad de ppar y procedimientos para su preparacion | |
| DOP2024000028A (es) | Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| NI202000014A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| MX2024013040A (es) | Pirfenidona enriquecida con deuterio y metodos para su uso | |
| CL2021002521A1 (es) | Compuestos heteocíclicos y sus usos. | |
| MX2022006862A (es) | Inhibidores duales de magl y faah. | |
| CO2023010940A2 (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
| UY35472A (es) | Compuestos y sus usos en la modulacion de la hemoglobina | |
| CL2024003870A1 (es) | Compuestos de degradación de wee1 y usos de los mismos | |
| DOP2022000127A (es) | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos. | |
| MX2018009189A (es) | Compuestos de anillo de siete miembros de pirimidina. | |
| AR131235A1 (es) | Formas cristalinas de n,n-dimetiltriptamina y métodos para usarlas | |
| CL2025000272A1 (es) | Derivados de arilo tricíclico y composiciones y métodos de los mismos | |
| CL2025003186A1 (es) | Moduladores de nk3 y usos de los mismos. | |
| CL2024001748A1 (es) | Usos de compuestos biciclicos para el tratamiento de enfermedades. | |
| CO2022002808A2 (es) | Proteínas de fusión nkg2d y sus usos | |
| CL2022002589A1 (es) | Tratamiento de trastornos respiratorios |